LACTOLOGY FOUNDATION

Roxatidine (ATC A02BA06) is an H2‑receptor antagonist used for acid‑related disorders, with relatively favorable safety in pregnancy (FDA category B) and very low toxico‑lactational risk based on measured low exposure in breastfed infants. Its pharmacokinetics and human milk data support use during breastfeeding when clinically indicated, especially compared with less studied or higher‑risk alternatives.

Active substance and class

Roxatidine is an antisecretory gastrointestinal drug from the H2‑receptor antagonist class, related to cimetidine, ranitidine, famotidine and nizatidine. It suppresses basal and stimulated gastric acid secretion via selective blockade of histamine H2 receptors on parietal cells, thereby promoting ulcer healing and relieving reflux‑related symptoms.

The ATC/DDD index lists roxatidine under A02BA06 within “H2‑receptor antagonists based on treatment of peptic ulcers.” Clinically, it is used in similar indications and dosing regimens to other H2‑blockers, but with a somewhat longer half‑life than ranitidine, allowing once‑ or twice‑daily dosing.

Indications and clinical use

Approved indications for roxatidine include: treatment of erosive esophagitis, short‑term treatment of active duodenal and benign gastric ulcers, long‑term prophylaxis of duodenal ulcer and gastric hypersecretory states, treatment of gastro‑oesophageal reflux, prevention of upper GI bleeding in critically ill patients, adjunctive use in corrosive acid ingestions, and symptomatic relief of heartburn. Off‑label, it has been included in some multi‑drug regimens for Helicobacter pylori eradication in adults and children, following the same rationale as other H2‑antagonists.

In many countries, clinical practice has gradually shifted toward proton‑pump inhibitors as first‑line therapy for acid‑related disorders, but H2‑receptor antagonists such as roxatidine are still considered acceptable options, particularly for milder disease or night‑time symptoms. This background is important when evaluating its role in special populations like pregnant and lactating women, where safety can outweigh maximal antisecretory potency.

Pharmacokinetics and disposition

Roxatidine is rapidly and almost completely absorbed after oral administration, with onset of effect within a few hours. In contrast to some other H2‑blockers, its elimination is predominantly renal rather than hepatic, which is clinically relevant in patients with liver disease but requires dose adjustment in significant renal impairment.

The plasma elimination half‑life is approximately 5 hours, which underlies the usual twice‑daily dosing but still allows once‑daily regimens in some indications. Its relatively short half‑life and moderate milk transfer also mean that timing feeds to avoid peak concentrations can further limit infant exposure, if necessary.

Excretion into breast milk

Your local data report a milk:plasma ratio for roxatidine between 1:1 and 3.4, depending on dose, with an average concentration of about 4.5 mg/L in mature human milk. Despite this measurable transfer, the resulting relative infant dose (RID) remains well below the commonly accepted 10% threshold that is generally considered compatible with breastfeeding.

Published reviews on H2‑receptor antagonists in breastfeeding conclude that, although direct data for each molecule are limited, use of any H2‑blocker in lactating mothers does not appear to pose significant risk and no adverse effects have been reported in breastfed infants. Roxatidine fits this pattern: milk concentrations are low to moderate, oral bioavailability in infants is limited, and the pharmacodynamic target (gastric H2 receptors) is not associated with serious toxicity at these exposures.

Toxicological profile and adverse effects

Roxatidine is generally well tolerated; the most frequent adverse effects are mild and include headache, dizziness, gastrointestinal discomfort, and infrequent skin reactions. Unlike some other H2‑antagonists, it has not been strongly linked to clinically significant endocrine effects (such as gynecomastia) or severe idiosyncratic hepatotoxicity at therapeutic doses.

In contrast to niperotidine (A02BA05), which was withdrawn for severe drug‑induced liver injury, roxatidine has not been associated with a comparable signal of acute liver failure or high‑grade hepatotoxicity and remains marketed in various regions. Its safety experience is therefore more consistent with other established H2‑blockers, making it a relatively low‑risk option when an H2 antagonist is needed in pregnancy or lactation.

Use in pregnancy

The local monograph assigns roxatidine to FDA pregnancy category B, reflecting that animal studies do not demonstrate fetal risk and human data, although limited, do not suggest an increase in congenital anomalies or adverse pregnancy outcomes. General guidance documents on reflux management in pregnancy state that H2‑receptor antagonists are considered acceptable for use when lifestyle measures and antacids are insufficient, and epidemiologic data do not show increased malformation risk with standard therapeutic use.

When choosing acid‑suppressive therapy in pregnancy, proton‑pump inhibitors (especially omeprazole) have extensive reassuring data, but H2‑antagonists such as roxatidine remain reasonable alternatives, particularly when there is prior good individual response or intolerance to PPIs. In all cases, the lowest effective dose and the shortest necessary duration should be used.

Use in lactation

Your local classification places roxatidine in toxico‑lactational category I, indicating that it is suitable for use during breastfeeding. This is supported by pharmacokinetic data (limited transfer, short half‑life) and by class‑level evidence that H2‑receptor antagonists do not pose a significant risk to the breastfed infant and have not been associated with clinically important adverse effects.

From a mechanistic standpoint, although milk levels can reach a few mg/L, the absolute infant dose remains small relative to therapeutic pediatric doses, and the drug’s pharmacology does not suggest serious toxicity at these exposures. Therefore, roxatidine is compatible with breastfeeding; routine infant monitoring can be limited to observation for non‑specific symptoms such as unusual irritability or gastrointestinal upset, which are unlikely.

Practical toxico‑lactologic recommendations

For pregnant patients with peptic ulcer disease or reflux who require more than antacids or alginates, roxatidine may be used when benefits outweigh risks, especially if there is previous effective use or intolerance to alternative H2‑blockers or PPIs. Non‑pharmacologic measures (dietary adjustment, head‑of‑bed elevation, avoiding late meals) should be optimized before and alongside pharmacotherapy.

In breastfeeding women, roxatidine can be considered a first‑line H2‑antagonist option where clinically indicated, given its favorable toxico‑lactological profile and your local category I classification. To further minimize infant exposure in very young or high‑risk infants, mothers may, if feasible, breastfeed just before taking a dose so that peak maternal and milk concentrations occur between feeds.